» Articles » PMID: 23446216

Linkage Between Anaplasma Marginale Outer Membrane Proteins Enhances Immunogenicity but is Not Required for Protection from Challenge

Overview
Date 2013 Mar 1
PMID 23446216
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The prevention of bacterial infections via immunization presents particular challenges. While outer membrane extracts are often protective, they are difficult and expensive to isolate and standardize and thus are often impractical for development and implementation in vaccination programs. In contrast, individual proteins, which are easily adapted for use in subunit vaccines, tend to be poorly protective. Consequently, identification of the specific characteristics of outer membrane-based immunogens, in terms of the antigen contents and contexts that are required for protective immunity, represents a major gap in the knowledge needed for bacterial vaccine development. Using as a model Anaplasma marginale, a persistent tick-borne bacterial pathogen of cattle, we tested two sets of immunogens to determine whether membrane context affected immunogenicity and the capacity to induce protection. The first immunogen was composed of a complex of outer membrane proteins linked by covalent bonds and known to be protective. The second immunogen was derived directly from the first one, but the proteins were individualized rather than linked. The antibody response induced by the linked immunogen was much greater than that induced by the unlinked immunogen. However, both immunogens induced protective immunity and an anamnestic response. These findings suggest that individual proteins or combinations of proteins can be successfully tested for the ability to induce protective immunity with less regard for overall membrane context. Once protective antigens are identified, immunogenicity could be enhanced by cross-linking to allow a reduced immunogen dose or fewer booster vaccinations.

Citing Articles

Immunogenic evaluation of LptD + LtgC as a bivalent vaccine candidate against Neisseria gonorrhoeae.

Noori Goodarzi N, Barzi S, Ajdary S, Chiani M, Yekaninejad M, Badmasti F J Transl Med. 2025; 23(1):261.

PMID: 40038701 PMC: 11877727. DOI: 10.1186/s12967-025-06256-1.


Genetically modified live vaccine offers protective immunity against wild-type Anaplasma marginale tick-transmission challenge.

Ferm J, Jaworski D, Stoll I, Kleinhenz M, Kocan K, Madesh S Vaccine. 2024; 42(24):126069.

PMID: 38880695 PMC: 11401762. DOI: 10.1016/j.vaccine.2024.06.036.


Immunization with Msp2 HVRs Is Less Effective than the Live Vaccine against Anaplasmosis.

Falghoush A, Ku P, Brayton K Vaccines (Basel). 2023; 11(10).

PMID: 37896947 PMC: 10610995. DOI: 10.3390/vaccines11101544.


Targeted mutagenesis in Anaplasma marginale to define virulence and vaccine development against bovine anaplasmosis.

Hove P, Madesh S, Nair A, Jaworski D, Liu H, Ferm J PLoS Pathog. 2022; 18(5):e1010540.

PMID: 35576225 PMC: 9135337. DOI: 10.1371/journal.ppat.1010540.


A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge.

Sarli M, Novoa M, Mazzucco M, Signorini M, Echaide I, de Echaide S PLoS One. 2020; 15(2):e0229301.

PMID: 32084216 PMC: 7034839. DOI: 10.1371/journal.pone.0229301.


References
1.
Huntley J, Conley P, Rasko D, Hagman K, Apicella M, Norgard M . Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infect Immun. 2008; 76(8):3664-71. PMC: 2493219. DOI: 10.1128/IAI.00374-08. View

2.
Silhavy T, Kahne D, Walker S . The bacterial cell envelope. Cold Spring Harb Perspect Biol. 2010; 2(5):a000414. PMC: 2857177. DOI: 10.1101/cshperspect.a000414. View

3.
Tebele N, McGuire T, Palmer G . Induction of protective immunity by using Anaplasma marginale initial body membranes. Infect Immun. 1991; 59(9):3199-204. PMC: 258153. DOI: 10.1128/iai.59.9.3199-3204.1991. View

4.
Turbyfill K, Hartman A, Oaks E . Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine. Infect Immun. 2000; 68(12):6624-32. PMC: 97759. DOI: 10.1128/IAI.68.12.6624-6632.2000. View

5.
Mann B, Ark N . Rationally designed tularemia vaccines. Expert Rev Vaccines. 2009; 8(7):877-85. PMC: 2748800. DOI: 10.1586/erv.09.51. View